Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
42 hedge funds and large institutions have $175M invested in Evelo Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
11% more funds holding
Funds holding: 38 → 42 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
32% less capital invested
Capital invested by funds: $258M → $175M (-$82.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$670K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$434K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$419K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$354K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.42M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$397K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$51K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$17.2K |
EVLO Hedge Fund Activity: Q3 2019 in Review
42 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2019, worth a combined $175M — down 32% from $258M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVLO positions and 1 closed out — a net gain of 4 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $670K. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.42M sold.
- 42 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2019, up from 38 in Q2 2019.
- Funds reported $175M of Evelo Biosciences, Inc. Common Stock stock for Q3 2019, down 32% quarter-over-quarter.
- 5 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +4 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2019 was BlackRock, an estimated $670K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2019 was Goldman Sachs, an estimated $2.42M sold.
Based on aggregated 13F filings for Q3 2019.